(Q35927598)

11 August 2017

1 reference

title

Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen (English)

1 reference

11 August 2017

Charles P Theuer

1

1 reference

11 August 2017

Bryan R Leigh

2

1 reference

11 August 2017

Pratik S Multani

3

1 reference

11 August 2017

Roberta S Allen

4

1 reference

11 August 2017

Bertrand C Liang

5

1 reference

11 August 2017

publication date

1 January 2004

1 reference

Biotechnology Annual Review

11 August 2017

published in

1 reference

11 August 2017

volume

10

1 reference

11 August 2017

page(s)

265-295

1 reference

11 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Epidemiology of lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Histologic conversion in the non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Transformed lymphoma: an Achilles' heel of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

World Health Organization Classification of lymphomas: a work in progress

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Long-term survival after histologic transformation of low-grade follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Follicular lymphoma: prognostic factors for response and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Hematopoietic and lymphoproliferative cancer among male veterans using the Veterans Administration Medical System

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

High-dose chlorambucil and dexamethasone for relapsed non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Fludarabine phosphate for the treatment of low grade lymphoid malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

2-Chlorodeoxyadenosine treatment of low-grade lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Low grade non-Hodgkin's lymphomas: disease control with mitoxanthrone monotherapy in patients refractory to conventional therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Results of MIME salvage regimen for recurrent or refractory lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agent

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Recent developments in radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Radioimmunotherapy for lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Diffuse large cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2804%2910011-2

7 January 2021

10.1016/S1387-2656(04)10011-2

Identifiers

DOI

0 references

1 reference